Prelude Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

Prelude Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-54,578	Closed	-$166K	–	1316
2023 Q4	$166K	Sell	54,578 -9,630	-15%	-$29.2K	0.01%	981
2023 Q3	$193K	Buy	64,208 +40,130	+167%	+$137K	0.01%	913
2023 Q2	$90.1K	Sell	24,078 -4,422	-16%	-$16.6K	0.01%	939
2023 Q1	$95.5K	Buy	+28,500	New	+$116K	0.01%	956
2022 Q3	–	Sell	-10,196	Closed	-$72K	–	1578
2022 Q2	$72K	Sell	10,196 -4	-0%	-$27	﹤0.01%	1457
2022 Q1	$74K	Buy	+10,200	New	+$69.3K	﹤0.01%	1451

Other funds holding AVIR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Prelude Capital Management's AVIR Position: Q1 2024 in Review

Prelude Capital Management sold out of Atea Pharmaceuticals (AVIR) in Q1 2024, closing a stake of 54,578 shares — an estimated $166K sold.

Prelude Capital Management first reported a position in AVIR in Q1 2022 and held it in 6 quarters. The position peaked at $193K in Q3 2023. 113 funds tracked by Wall St. Rank hold AVIR as of Q1 2024.

Prelude Capital Management reported no remaining Atea Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Prelude Capital Management sold 54,578 Atea Pharmaceuticals shares in Q1 2024, an estimated $166K.
Prelude Capital Management first reported a position in Atea Pharmaceuticals in Q1 2022 and held it in 6 quarters.
Prelude Capital Management's Atea Pharmaceuticals position peaked at $193K in Q3 2023.
113 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2024.

Based on Prelude Capital Management's 13F filing for Q1 2024, filed 15 May 2024.